Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

dMed Biopharma, a China, US, EU Clinical CRO, Raises $50 Million

publication date: Oct 16, 2019

dMed Biopharma, a Shanghai CRO that offers clinical trial services in China, the US and the EU, completed a Series B financing of nearly $50 million, led by Vivo Capital and joined by Legend Capital, Qiming Venture Partners and Lilly Asia Ventures. Launched three years ago, dMed considers itself a "next-gen" clinical CRO with efficient operations, IT services and expertise in cross-border global trials. The company has 600 employees. Recently, dMed acquired Target Health, a full service New York-based CRO, to expand its global offerings and add new technologies. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here